1. Medtech Insight
  2. >>Minute Insights

Minute Insight: OxfordVR’s Virtual Reality Program Treats Agoraphobia In Trial

 
• By Reed Miller

Results of a 346-patient randomized trial run by the UK’s National Health Service showed the automated virtual reality system developed by researchers at Oxford University helped people with agoraphobia re-engage with day-to-day activities outside their home.

Minute Insight
• Source: Informa/Alamy

Virtual reality (VR) simulations can help housebound people who are extremely anxious going outside to re-engage with the world outside without distress.

OxfordVR, an University of Oxford “spinout company” founded in 2018, has developed gameChange, a VR program to help people overcome agoraphobia – Greek for "fear of the marketplace" – which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Minute Insights

Minute Insight: Haemonetics Buys OpSens To Add Fiber-Optic Sensors For Intervention

 
• By Reed Miller

Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.

Minute Insight: Best Buy Will Sell Dexcom CGM

 
• By Reed Miller

The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.

Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators

 
• By Barnaby Pickering

Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

 
• By Reed Miller

Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.

More from Medtech Insight

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.